Although Pcal therapy elevated cardiac adiponectin levels in apolipoprotein-E deficient mice [50], it showed limited effects on hepatic adiponectin and leptin levels, as well as the expression of their receptors, PPARα, PPARγ, and SREBP-1 in rats with non-alcoholic fatty liver disease [51]. Here, SREBF1 is linked to alcoholic fatty liver disease.